chondroitin and Pain

chondroitin has been researched along with Pain* in 15 studies

Reviews

6 review(s) available for chondroitin and Pain

ArticleYear
Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review.
    Osteoarthritis and cartilage, 2012, Volume: 20, Issue:8

    Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. Collagen derivatives are candidates for disease-modifying OA drugs. This group of derivatives can be divided into undenatured collagen (UC), gelatine and collagen hydrolysate (CH). Collagen derivatives are marketed as having direct chondroprotective action and reducing complaints of OA. This review summarizes the evidence for the effectiveness of symptomatic and chondroprotective treatment with collagen derivatives in patients with OA.. Eligible randomised controlled trials (RCTs) and quasi-RCTs were identified by searching PubMed, Embase and the Cochrane Central Register of Controlled Trials until November 2011. Methodological quality was assessed using methods of the Cochrane Back Review Group.. Eight studies were identified: six on CH, two on gelatine, and one on UC. The pooled mean difference based on three studies for pain reduction measured with the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index comparing CH with placebo was -0.49 (95% CI -1.10-0.12). However, some studies report significant between-group differences in pain when measured with a visual analogical scale (VAS) or other instruments, or when CH is compared with glucosamine sulphate. For disability no significant between-group mean differences were found when comparing CH with placebo. Gelatine compared with placebo and with alternative therapies was superior for the outcome pain. UC compared with glucosamine+chondroitin showed no significant between-group differences for pain and disability. The most reported adverse events of collagen derivatives were mild to moderate gastro-intestinal complaints. The overall quality of evidence was moderate to very low.. There is insufficient evidence to recommend the generalized use of CHs in daily practice for the treatment of patients with OA. More independent high-quality studies are needed to confirm the therapeutic effects of collagen derivatives on OA complaints.

    Topics: Chondroitin; Collagen; Female; Gelatin; Glucosamine; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Pain Measurement; Protein Hydrolysates; Randomized Controlled Trials as Topic; Treatment Outcome

2012
Arthritis disease - the use of complementary therapies.
    Australian family physician, 2010, Volume: 39, Issue:9

    While effective drugs are available to deal with the symptoms and modify the progress of osteoarthritis and rheumatoid arthritis, these may cause serious adverse events and not all patients will obtain relief. Many people with these diseases use complementary medicines.. This article presents an overview of the evidence for the most promising complementary therapies for osteoarthritis and rheumatoid arthritis, with other information that general practitioners need to know.. There is reasonable evidence to support the use of glucosamine, avocado/soybean unsaponifiables and chondroitin in osteoarthritis, and omega-3 fatty acids and gammalinolenic acid in rheumatoid arthritis. However, no current evidence does not equate to lack of effectiveness. Rigorous research into the use of complementary medicines in arthritis is evolving and many of the systematic reviews used in preparation of this article are being updated every few years to incorporate new trial evidence as it becomes available.

    Topics: Arthritis, Rheumatoid; Chondroitin; Complementary Therapies; Disease Progression; Fatty Acids, Omega-3; General Practitioners; Glucosamine; Herbal Medicine; Humans; Musculoskeletal Diseases; Nutritional Status; Osteoarthritis; Pain; Pain Management; Soybean Proteins

2010
Drug selection in a patient with a history of hypersensitivity reactions: a practical approach for the orthopedist.
    Orthopedics, 2007, Volume: 30, Issue:11

    Drug allergies are specific to characteristics of the medication's chemical structure.

    Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Chondroitin; Drug Hypersensitivity; Glucosamine; Humans; Infections; Orthopedics; Osteoarthritis; Osteoporosis; Pain; Sensory System Agents

2007
Treatment of primary and secondary osteoarthritis of the knee.
    Evidence report/technology assessment, 2007, Issue:157

    Systematic review of outcomes of three treatments for osteoarthritis (OA) of the knee: intra-articular viscosupplementation; oral glucosamine, chondroitin or the combination; and arthroscopic lavage or debridement.. We abstracted data from: 42 randomized, controlled trials (RCTs) of viscosupplementation, all but one synthesized among six meta-analyses; 21 RCTs of glucosamine/chondroitin, 16 synthesized among 6 meta-analyses; and 23 articles on arthroscopy. The search included foreign-language studies and relevant conference proceedings.. The review methods were defined prospectively in a written protocol. We sought systematic reviews, meta-analyses, and RCTs published in full or in abstract. Where randomized trials were few, we sought other study designs. We independently assessed the quality of all primary studies.. Viscosupplementation trials generally report positive effects on pain and function scores compared to placebo, but the evidence on clinical benefit is uncertain, due to variable trial quality, potential publication bias, and unclear clinical significance of the changes reported. The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), a large (n=1,583), high-quality, National Institutes of Health-funded, multicenter RCT showed no significant difference compared to placebo. Glucosamine sulfate has been reported to be more effective than glucosamine hydrochloride, which was used in GAIT, but the evidence is not sufficient to draw conclusions. Clinical studies of glucosamine effect on glucose metabolism are short term, or if longer (e.g., 3 years), excluded patients with metabolic disorders. The best available evidence for arthroscopy, a single sham-controlled RCT (n=180), showed that arthroscopic lavage with or without debridement was equivalent to placebo. The main limitations of this trial are the use of a single surgeon and enrollment of patients at a single Veterans Affairs Medical Center. No studies reported separately on patients with secondary OA of the knee. The only comparative study was an underpowered, poor-quality trial comparing viscosupplementation to arthroscopy with debridement.. Osteoarthritis of the knee is a common condition. The three interventions reviewed in this report are widely used in the treatment of OA of the knee, yet the best available evidence does not clearly demonstrate clinical benefit. Uncertainty regarding clinical benefit can be resolved only by rigorous, multicenter RCTs. In addition, given the public health impact of OA of the knee, research on new approaches to prevention and treatment should be given high priority.

    Topics: Aged; Arthroscopy; Chondroitin; Debridement; Drug Therapy, Combination; Female; Glucosamine; Humans; Hyaluronic Acid; Injections, Intra-Articular; Knee; Male; Middle Aged; Osteoarthritis, Knee; Pain; Synovial Fluid; Therapeutic Irrigation; Treatment Outcome

2007
Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis.
    Journal of the American Academy of Nurse Practitioners, 2006, Volume: 18, Issue:10

    To evaluate past and current evidence from randomized controlled trials on the efficacy of glucosamine sulfate (GS), glucosamine hydrochloride (GH), and chondroitin sulfate (CS) for the treatment of osteoarthritis (OA).. An extensive review of four meta-analyses and a review of the findings of the recently published Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) funded by the National Institutes of Health.. Review of previous studies on the efficacy of GS, GH, and CS in the treatment of OA showed inconclusive results because of weak research design. The GAIT attempted to provide clarity on the use of GH and CS in treating knee pain from OA by using a rigorous research design to elicit cause and effect. The GAIT results showed that GH and CS were not effective in reducing knee pain in the study group overall; however, these may be effective in combination for patients with moderate-to-severe knee pain.. There is now clinical evidence indicating that recommending GS, GH, and CS for the treatment of mild knee pain from OA is ineffective. Further research needs to be done to identify specific characteristics in patients that results in a positive response. Until the findings of the GAIT undergo further peer review, the results of the research needs to be interpreted with caution.

    Topics: Chondroitin; Drug Combinations; Evidence-Based Medicine; Glucosamine; Health Services Needs and Demand; Humans; Meta-Analysis as Topic; Nonprescription Drugs; Osteoarthritis; Pain; Patient Education as Topic; Practice Guidelines as Topic; Primary Health Care; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index; Treatment Outcome

2006
An essay on the biology of osteoarthritis.
    Arthritis and rheumatism, 1969, Volume: 12, Issue:2

    Topics: Aging; Cartilage, Articular; Chondroitin; Humans; Hyaluronoglucosaminidase; Osteoarthritis; Pain; Polysaccharides; RNA; Synovial Fluid

1969

Trials

2 trial(s) available for chondroitin and Pain

ArticleYear
Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate.
    Journal of animal physiology and animal nutrition, 2012, Volume: 96, Issue:5

    The investigation was conducted on client-owned moderately arthritic dogs with two objectives: (i) to evaluate therapeutic efficacy of type-II collagen (UC-II) alone or in combination with glucosamine hydrochloride (GLU) and chondroitin sulphate (CHO), and (ii) to determine their tolerability and safety. Dogs in four groups (n = 7-10), were treated daily for a period of 150 days with placebo (Group-I), 10 mg active UC-II (Group-II), 2000 mg GLU + 1600 mg CHO (Group-III), and UC-II + GLU + CHO (Group-IV). On a monthly basis, dogs were evaluated for observational pain (overall pain, pain upon limb manipulation, and pain after physical exertion) using different numeric scales. Pain level was also measured objectively using piezoelectric sensor-based GFP for peak vertical force and impulse area. Dogs were also examined every month for physical, hepatic (ALP, ALT and bilirubin) and renal (BUN and creatinine) functions. Based on observations, significant (p < 0.05) reduction in pain was noted in Group-II, III, and IV dogs. Using GFP, significant increases in peak vertical force (N/kg body wt) and impulse area (N s/kg body wt), indicative of a decrease in arthritis associated pain, were observed in Group-II dogs only. None of the dogs in any group showed changes in physical, hepatic or renal functions. In conclusion, based on GFP data, moderately arthritic dogs treated with UC-II (10 mg) showed a marked reduction in arthritic pain with maximum improvement by day 150. UC-II, GLU and CHO operate through different mechanisms of action, and were well tolerated over a period of 150 days.

    Topics: Animals; Arthritis; Biomechanical Phenomena; Chondroitin; Collagen Type II; Dog Diseases; Dogs; Drug Administration Schedule; Glucosamine; Lameness, Animal; Pain

2012
Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.
    Osteoarthritis and cartilage, 2007, Volume: 15, Issue:11

    This preliminary study sought to determine whether using 1500/1200mg of glucosamine hydrochloride and chondroitin sulfate (GH/CS) is effective, both separately and combined with exercise, compared to a placebo plus exercise program in improving physical function, pain, strength, balance, and mobility in older adults with knee osteoarthritis (OA).. This double-blind, placebo-controlled, randomized clinical trial lasted 12 months. Participants included 89 older adults (age>/=50 years) with knee OA randomized to either GH/CS or placebo group. Phase I was a 6-month trial comparing the effects of assignment to either GH/CS or placebo. Phase II added 6 months of exercise for both groups. The primary outcome measure was Western Ontario and McMaster University Osteoarthritis Index (WOMAC) function, and secondary outcome measures included WOMAC pain, 6-min walk, balance, and knee strength.. Of the 89 randomized participants, 72 (81%) completed the study. The median pill compliance was 94% and 95% in Phase I, and, in Phase II, 97% and 91% for the GH/CS and placebo groups, respectively. Median exercise compliance during Phase II was 77% for the GH/CS group and 78% for the placebo group. WOMAC function and pain did not differ significantly between the groups at 6- or 12-month follow-up. There were also no significant differences between the groups in 6-min walk or knee strength; however, balance was better in the placebo group with approximately a 10% difference compared to the GH/CS group.. The GH/CS group was not superior to the placebo group in function, pain, or mobility after both phases of the intervention (pill only and pill plus exercise).

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analysis of Variance; Chondroitin; Double-Blind Method; Exercise Therapy; Female; Glucosamine; Humans; Male; Middle Aged; Osteoarthritis, Knee; Pain; Patient Compliance; Severity of Illness Index

2007

Other Studies

7 other study(ies) available for chondroitin and Pain

ArticleYear
Evidence-based tailored conservative treatment of knee and hip osteoarthritis: between knowing and doing.
    Scandinavian journal of rheumatology, 2011, Volume: 40, Issue:3

    Insufficient data are available on the efficacy of combined conservative interventions recommended by treatment guidelines for knee/hip osteoarthritis (OA). The aims of this observational cohort study were (i) to estimate the results of an evidence-based 12-week tailored multimodal conservative treatment protocol for patients with knee/hip OA and (ii) to identify predictors for response.. After obtaining data on previous OA-related interventions, multimodal treatment was offered to patients with knee and/or hip OA at a specialized outpatient clinic. Treatment with analgesics was tailored using a numeric rating scale (NRS) for pain, aiming for NRS ≤ 4. The following outcome measures were assessed: (i) the proportion of patients fulfilling OMERACT-OARSI (Outcome Measures in Rheumatoid Arthritis Clinical Trials/Osteoarthritis Research Society International) responder criteria and (ii) the proportion of patients with NRS pain ≤ 4 after 12 weeks.. A total of 183 out of 299 patients was included. OMERACT-OARSI responder criteria were fulfilled at 12 weeks in 47% of patients; 39% reached NRS pain ≤ 4. The only independent predictor for response was the number of previously used non-steroidal anti-inflammatory drugs (NSAIDs). The majority of patients had not been exposed adequately to conservative treatment modalities for knee and/or hip OA in the past (81%).. Evidence-based multimodal conservative treatment using a standardized protocol for knee and/or hip OA is feasible and successful in 47% of patients. In general, response could not be predicted. Basic first-line recommended conservative treatment options have not been used adequately prior to referral to secondary care in the vast majority of patients.

    Topics: Analgesics; Chondroitin; Cohort Studies; Dietary Supplements; Evidence-Based Medicine; Female; Glucosamine; Humans; Male; Middle Aged; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Pain Measurement; Physical Therapy Modalities; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome

2011
Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses.
    Journal of veterinary pharmacology and therapeutics, 2009, Volume: 32, Issue:6

    The present investigation evaluated arthritic pain in horses receiving daily placebo, undenatured type II collagen (UC-II) at 320, 480, or 640 mg (providing 80, 120, and 160 mg active UC-II, respectively), and glucosamine and chondroitin (5.4 and 1.8 g, respectively, bid for the first month, and thereafter once daily) for 150 days. Horses were evaluated for overall pain, pain upon limb manipulation, physical examination, and liver and kidney functions. Evaluation of overall pain was based upon a consistent observation of all subjects during a walk and a trot in the same pattern on the same surface. Pain upon limb manipulation was conducted after the walk and trot. It consisted of placing the affected joint in severe flexion for a period of 60 sec. The limb was then placed to the ground and the animal trotted off. The response to the flexion test was then noted with the first couple of strides the animal took. Flexion test was consistent with determining clinically the degree of osteoarthritis in a joint. Horses receiving placebo showed no change in arthritic condition, while those receiving 320 or 480 or 640 mg UC-II exhibited significant reduction in arthritic pain (P < 0.05). UC-II at 480 or 640 mg dose provided equal effects, and therefore, 480 mg dose was considered optimal. With this dose, reduction in overall pain was from 5.7 +/- 0.42 (100%) to 0.7 +/- 0.42 (12%); and in pain upon limb manipulation from 2.35 +/- 0.37 (100%) to 0.52 +/- 0.18 (22%). Although glucosamine and chondroitin treated group showed significant (P < 0.05) reduction in pain compared with pretreated values, the efficacy was less compared with that observed with UC-II. In fact, UC-II at 480 or 640 mg dose was found to be more effective than glucosamine and chondroitin in arthritic horses. Clinical condition (body weight, body temperature, respiration rate, and pulse rate), and liver (bilirubin, GGT, and ALP) and kidney (BUN and creatinine) functions remained unchanged, suggesting that these supplements were well tolerated.

    Topics: Animals; Chondroitin; Collagen Type II; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glucosamine; Horse Diseases; Horses; Osteoarthritis; Pain

2009
Carpal tunnel syndrome, diabetic neuropathy, fibromyalgia, glucosamine and chondroitin, hypnosis in pain management, marijuana for pain.
    Journal of pain & palliative care pharmacotherapy, 2007, Volume: 21, Issue:2

    This feature presents information for patients in a question and answer format. It is written to simulate actual questions that many pain patients ask and to provide answers in a context and language that most pain patients will comprehend. Issues addressed in this issue are carpel tunnel syndrome, fibromyalgia, glucosamine and chondroitin, hypnosis, marijuana.

    Topics: Cannabis; Carpal Tunnel Syndrome; Chondroitin; Diabetic Neuropathies; Drug Combinations; Fibromyalgia; Glucosamine; Humans; Hypnosis; Pain; Pain Management; Phytotherapy; Plant Preparations

2007
Managing osteoarthritis of the knee: glucosamine-chondroitin should be prescribed by doctors.
    BMJ (Clinical research ed.), 2005, Mar-19, Volume: 330, Issue:7492

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Chondroitin; Glucosamine; Humans; Osteoarthritis, Knee; Pain

2005
Are glucosamine and chondroitin effective in treating osteoarthritis?
    The Journal of family practice, 2000, Volume: 49, Issue:6

    Topics: Chondroitin; Disabled Persons; Drug Therapy, Combination; Glucosamine; Humans; Meta-Analysis as Topic; Osteoarthritis; Pain; Reproducibility of Results; Treatment Outcome

2000
Potential side effects of treatment with glucosamine and chondroitin.
    Arthritis and rheumatism, 2000, Volume: 43, Issue:12

    Topics: Chondroitin; Glucosamine; Hypertension; Nonprescription Drugs; Osteoarthritis; Pain; Proteinuria

2000
Treatment of protruded lumbar intervertebral discs with chymopapain (Discase).
    Journal of neurosurgery, 1973, Volume: 39, Issue:2

    Topics: Adult; Aged; Cerebrospinal Fluid Proteins; Chondroitin; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Intervertebral Disc Displacement; Male; Middle Aged; Mucoproteins; Pain; Papain; Peptide Hydrolases; Spinal Puncture

1973